Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026

Core Viewpoint - Syndax Pharmaceuticals will report its fourth quarter and full year 2025 financial results on February 26, 2026, and will host a conference call and live audio webcast to discuss the results and provide a business update [1]. Group 1: Financial Results Announcement - The earnings release is scheduled for Thursday, February 26, 2026 [1]. - A conference call and live audio webcast will take place at 4:30 p.m. ET on the same day [1]. Group 2: Access Information - The live audio webcast and accompanying slides can be accessed through the Events & Presentations page in the Investors section of the Company's website [2]. - Conference ID for the call is Syndax4Q25, with domestic dial-in number 800-590-8290 and international dial-in number 240-690-8800 [2]. - A replay of the conference call will be available approximately 24 hours after the event and will remain accessible for 90 days [2]. Group 3: Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on innovative cancer therapies [3]. - Key products in the pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody targeting the CSF-1 receptor [3]. - The company is committed to advancing cancer care and is conducting several clinical trials across various treatment stages [3].